A dual label oligonucleotide ligation assay for detection of the CYP2C19*1, CYP2C19*2, and CYP2C19*3 alleles involving time-resolved fluorometry

被引:11
|
作者
Bathum, L
Hansen, TS
Horder, M
Brosen, K
机构
[1] Odense Univ Hosp, Dept Clin Biochem, DK-5000 Odense C, Denmark
[2] Odense Univ, Dept Clin Pharmacol, DK-5230 Odense, Denmark
关键词
CYP2C19; genotyping; genetic polymorphism;
D O I
10.1097/00007691-199802000-00001
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
CYP2C19 (S-mephenytoin hydroxylase) is a polymorphically expressed enzyme. Currently, two defective alleles are known-CYP2C19*2 and CYP2C19*3. The authors have developed an oligonucleotide ligation assay to detect these two alleles. This assay combines the hybridization of one common, biotinylated capture probe and two allele-specific probes to the target DNA, with the ability of a DNA ligase to distinguish mismatched nucleotides. The probes are only ligated if they are base paired correctly to the target strand. The biotin is bound to streptavidin, and all DNA not covalently bound to the biotin-labeled capture probe, is removed in a washing procedure. The allele-specific probes are labeled with either europium or samarium, and their emission can be measured simultaneously. The ratio between the emission separates the genotypes. This method was applied on DNA from 19 whites and 21 Vietnamese living in Denmark. All genotypes determined by the assay were consistent with the results from restriction enzyme cleavage. There were 12 poor metabolizers; 10 homozygous CYP2C19*2/CYP2C19*2, one heterozygous CYP2C19*2/CYP2C19*3, and one heterozygous CYP2C19*1/CYP2C19*2. The authors conclude that this assay is well-suited for a high throughput of samples in a routine laboratory. The finding of an apparently heterozygous CYP2C19*1/CYP2C19*2 poor metabolizer, confirms that there are still unknown mutations in CYP2C19.
引用
收藏
页码:1 / 6
页数:6
相关论文
共 50 条
  • [31] Effects of CYP2C9 and CYP2C19 genetic polymorphisms on the pharmacokinetics and pharmacodynamics of gliclazide in healthy subjects
    Kang, Pureum
    Cho, Chang-Keun
    Jang, Choon-Gon
    Lee, Seok-Yong
    Lee, Yun Jeong
    Choi, Chang-Ik
    Bae, Jung-Woo
    ARCHIVES OF PHARMACAL RESEARCH, 2023, 46 (05) : 438 - 447
  • [32] The effects of CYP2C9 and CYP2C19 genetic polymorphisms on the pharmacokinetics and pharmacodynamics of glipizide in Chinese subjects
    Bo Tan
    Yi-Fan Zhang
    Xiao-Yan Chen
    Xiao-Hua Zhao
    Guo-Xin Li
    Da-Fang Zhong
    European Journal of Clinical Pharmacology, 2010, 66 : 145 - 151
  • [33] The effects of CYP2C9 and CYP2C19 genetic polymorphisms on the pharmacokinetics and pharmacodynamics of glipizide in Chinese subjects
    Tan, Bo
    Zhang, Yi-Fan
    Chen, Xiao-Yan
    Zhao, Xiao-Hua
    Li, Guo-Xin
    Zhong, Da-Fang
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2010, 66 (02) : 145 - 151
  • [34] Effects of CYP2C9 and CYP2C19 genetic polymorphisms on the pharmacokinetics and pharmacodynamics of gliclazide in healthy subjects
    Pureum Kang
    Chang-Keun Cho
    Choon-Gon Jang
    Seok-Yong Lee
    Yun Jeong Lee
    Chang-Ik Choi
    Jung-Woo Bae
    Archives of Pharmacal Research, 2023, 46 : 438 - 447
  • [35] The contribution of the enzymes CYP2D6 and CYP2C19 in the demethylation of artemether in healthy subjects
    M. A. Van Agtmael
    C. A. A. Van Der Graaf
    T. K. Dien
    R. P. Koopmans
    C. J. Van Boxtel
    European Journal of Drug Metabolism and Pharmacokinetics, 1998, 23 : 429 - 436
  • [36] The contribution of the enzymes CYP2D6 and CYP2C19 in the demethylation of artemether in healthy subjects
    Van Agtmael, MA
    Van der Graaf, CAA
    Dien, TK
    Koopmans, RP
    Van Boxtel, CJ
    EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS, 1998, 23 (03) : 429 - 436
  • [37] The prevalence of CYP2D6 and CYP2C19 genotypes in a population of healthy Dutch volunteers
    Tamminga, WJ
    Wemer, J
    Oosterhuis, B
    de Zeeuw, RA
    de Leij, LFMH
    Jonkman, JHG
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2001, 57 (10) : 717 - 722
  • [38] Possible role of CYP2C9 & CYP2C19 single nucleotide polymorphisms in drug refractory epilepsy
    Lakhan, Ram
    Kumari, Ritu
    Singh, Kavita
    Kalita, Jayanti
    Misra, Usha Kant
    Mittal, Balraj
    INDIAN JOURNAL OF MEDICAL RESEARCH, 2011, 134 (03) : 295 - 301
  • [39] A meta-analysis of effects of CYP2C9 and CYP2C19 polymorphisms on phenytoin pharmacokinetic parameters
    Kanjanasilp, Juntip
    Sawangjit, Ratree
    Phanthaisong, Sirikhwan
    Borihanthanawuth, Wongvaruth
    PHARMACOGENOMICS, 2021, 22 (10) : 629 - 640
  • [40] Evaluation of the influence of sex and CYP2C19 and CYP2D6 polymorphisms in the disposition of citalopram
    Fudio, Salvador
    Borobia, Alberto M.
    Pinana, Enrique
    Ramirez, Elena
    Tabares, Beatriz
    Guerra, Pedro
    Carcas, Antonio
    Frias, Jesus
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2010, 626 (2-3) : 200 - 204